18:52 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Aminex shows MYCN is a regulator of the polyamine pathway

Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable...
20:31 , Feb 1, 2019 |  BC Extra  |  Preclinical News

Aminex shows MYCN is a regulator of the polyamine pathway

Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable...
19:02 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million on June 20 in an untranched series B round. The company declined to name its investors. The company also said it dosed the first patient in a...
14:24 , Jun 20, 2018 |  BC Extra  |  Financial News

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million in an untranched series B round. The company declined to name its investors. The company said Wednesday that it dosed the first patient in a Phase I...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Financial News

Aminex Therapeutics completes venture financing

Aminex Therapeutics Inc. , Kirkland, Wash.   Business: Cancer   Date completed: 2015-11-09   Type: Venture financing   Raised: $4 million   Investor: New investors  ...
07:00 , Apr 9, 2009 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Squamous cell carcinoma of the head and neck (SCCHN) Polyamine transport An SAR study characterized a series of lipophilic lysine-spermine...
07:00 , Apr 9, 2009 |  BC Innovations  |  Targets & Mechanisms

Next-gen polyamine attack

The development of eflornithine monotherapy to treat cancer suffered a significant setback in 2004 when Ilex Oncology Inc. , since acquired by Genzyme Corp. , reported that the polyamine biosynthesis inhibitor failed to prevent recurrence...